Lisata Therapeutics Inc LSTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.48
- Day Range
- $3.41–3.48
- 52-Week Range
- $1.81–5.07
- Bid/Ask
- $3.41 / $3.46
- Shares Outstanding
- 9.11M
- Market Cap
- $31.51M
- Volume/Avg
- 91,439 / 103,506
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 179.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.lisata.com
Valuation
|
Metric
|
LSTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.90 |
Price/Sales | 179.89 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LSTA
|
|---|---|
Quick Ratio | 3.94 |
Current Ratio | 4.23 |
Interest Coverage | — |
Quick Ratio
LSTA
Profitability
|
Metric
|
LSTA
|
|---|---|
Return on Assets (Normalized) | −71.10% |
Return on Equity (Normalized) | −85.52% |
Return on Invested Capital (Normalized) | −86.62% |
Return on Assets
LSTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vtgztwctx | Xkyvw | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dbywgxblv | Bzncrqf | $64B | |||
| argenx SE ADR
ARGX
| Fnkrfrlqv | Wsdj | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ngjbfyp | Gwmymfs | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Qxcxtmcsd | Xrrpm | $24B | |||
| BioNTech SE ADR
BNTX
| Rrsmmgl | Flks | $22B | |||
| Incyte Corp
INCY
| Dgcmdxydz | Dbbps | $20B | |||
| Moderna Inc
MRNA
| Wkmrqssks | Vjmd | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Gkjdvblh | Vklq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Wlgxncz | Rnd | $13B |
United States